Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply Dr Lempert raises several issues, which we believe are mistaken or do not affect the interpretation of our results. As described,1 only participants at sites with more than 5 enrolled children were eligible for long-term follow-up for logistical reasons, which reduced the proportion of the original cohort that was enrolled in the follow-up study. The 15-year examination was completed by 152 of 188 eligible participants (80.9%). We compared patients who participated in follow-up with those who did not and noted in the article that those who participated had slightly better VA at 2 years than those who did not (20/25 vs 20/32, respectively), which could have resulted in a slight overestimate of VA at age 15 years. In addition, 147 participants in Table 1 noted by Dr Lempert were only those who completed the visit at age 15 years and had VA tested with the electronic Early Treatment Diabetic Retinopathy Study testing protocol (E-ETDRS).2 Five participants had VA tested with a method other than E-ETDRS and were not included in the primary results.
Repka MX, Kraker RT, Holmes JM, . Atropine vs Patching—Reply. JAMA Ophthalmol. 2015;133(5):619-620. doi:10.1001/jamaophthalmol.2014.6131